Cardiac death from atherosclerosis is common in hemodialysis patients. Human serum paraoxonase (PON1), an esterase, is associated with high-density lipoprotein and inhibits the susceptibility to oxidization of low-density lipoprotein (LDL). The PON1 genetic polymorphisms of 192 Gln/Arg and 55 Leu/Met in the amino acid sequence are partly involved in the PON1 enzyme activity. We investigated the PON1 enzyme activities for paraoxon (paraoxonase) and phenylacetate (arylesterase), and the two polymorphisms in 96 patients undergoing hemodialysis and in 136 normal controls.
Introduction
Human serum paraoxonase (PON1) is an esterase that hydrolyzes aromatic carboxylic acid esters, organophosphates, and carbamates (1). PON1 associates with apolipoprotein (apo) A-I and apo J in high-density lipoprotein (HDL) (2), and has been shown to reduce the susceptibility of low-density lipoprotein (LDL) to lipid peroxidation (3-6).
The serum activity of PON1 decreases in patients with a variety of diseases, such as myocardial infarction (7), familial hypercholesterolemia (8), diabetes mellitus (8-10) or uremia (11). The activity also varies by genetic basis among healthy individuals (1).
This protein has two polymorphic sites which are Leu-Met at position 55 of the amino acid sequence (L/M), and GInArg at position 192 (Q/R) (12). Both polymorphisms are involved in serum PON1 concentrations or paraoxonase activity which is measured using paraoxon as a substrate (12,13). The activity in subjects with the RR genotype is higher than in those with QQ, and the activity with the LL genotype is higher than in those with MM. The activity in each heterozygote shows a middle level. However, it has also been shown that arylesterase activity, the hydrolysing activity of PON1 for phenylacetate, is independent of those gene polymorphisms (12). The Q/R polymorphism has been reported to be associated with coronary heart disease (CHD) (14,15), although there have also been several contrasting studies (16) (17) (18) .
Cardiac death is the most frequent cause of death in patients undergoing hemodialysis (19), and one important cardiac disease in such patients is myocardial infarction which results from atherogenesis (20) . Oxidized LDL is a major factor in the acceleration of atherosclerosis (21), and such abnormal lipoproteins may be implicated in the development of CHD in uremic patients (22). Schiavon et a/. reported that paraoxonase activity was significantly reduced in uremic patients and suggested that altered HDL subfraction was a principal cause of the reduction, the higher frequency of alloenzyme B being another possibility (11). In that study, the frequency of the A and B allozymes, a genetic polymorphism, was estimated by a different response to NaCI. The allozyme is caused by the Q/R polymorphism which can be more accurately distinguished by genetic analysis.
We therefore investigated whether the 192L/M polymorphism was associated with the decreased enzyme activity in hemodialysis patients, and we also investigated the 55Q/R polymorphism to analyze more completely the genetic influence on the activity. In addition, we measured not only paraoxonase activity but also arylesterase activity to determine whether the decrease in PON1 enzyme activity is specific for paraoxon.
We found a decrease in both paraoxonase and arylesterase activities in hemodialysis patients, which were independent of the genetic polymorphisms.
Materials and Methods

Subjects
Patients undergoing hemodialysis (n=96 ; male/ female, 57/39) were recruited from the outpatient clinics of three hospitals between November 1997 and February 1998. The mean duration of hemodialysis was 3.9 years (0-22 years). The subjects had no history of cardiovascular disease during the 6 months prior to the study. Their clinical characteristics are shown in Table 1 . CHD was defined as any one of the following : 1) acute myocardial infarction or confirmed non-acute myocardial infarction based on serial readings of baseline and bien- 
Statistical analysis
All values are presented as the mean +standard deviation. Comparison of variables between two groups was performed using the unpaired t test. The values before and after hemodialysis were compared by the paired t test. Genotype frequencies were estimated by a chisquare test. All analysis including regression analysis was performed using a software program for a personal computer (JMP, ver 3.1, SAS Institute Inc. Cary, NC). p values <0.05 were considered significant.
Results
Paraoxonase and arylesterase activities As shown in Fig. 1 , paraoxonase activity was significantly lower in patients than in control subjects (97+43 vs 155+57 ,umol/min/l, respectively).
The arylesterase activity was also significantly lower in patients than in controls (71 +20 vs 92+22 mmol/min/l).
Since PON1 was associated with apo A-I on HDL, the PON1 mass may be accompanied by apo A-I mass. Therefore, the ratio of is not only an impairment of activity for a specific substrate. Several mechanisms are possible for the decrease in PON1 enzyme activities in hemodialysis patients. The mechanism does not appear to be directly and immediately caused by hemodialysis, because paraoxonase activity following hemodialysis was relatively increased. This increase probably resulted from a blood concentration caused by hemodialysis, although the activity after hemodialysis was still lower when compared with that in the control subjects indicating that the decreased activity in patients was not simply caused by dilution of circulating blood.
It has been shown that paraoxonase activity is decreased in subjects with CHD (7) or diabetes mellitus (8-10), and a certain percentage of the patients had these diseases in this study (25% and 21%, respectively). Therefore, we classified patients into subgroups based on the presence of these diseases and compared their paraoxonase and arylesterase activities with those in control subjects (Table 3 ). Both activities in each patient subgroup were lower than those in controls, indicating that the presence of these diseases was not a major cause of the decreased activity in patients.
Since Schiavon et al. (11) reported a higher frequency of alloenzyme B in uremic patients, we investigated PON1 polymorphisms in patients and controls by genetic analysis which could more precisely detect the genetic influence on PON1 enzyme activity. Both polymorphisms (55 L/M and 192 Q/R) were involved in the paraoxonase activity, but not in the arylesterase activity, among patients as well as controls.
Paraoxonase activity was higher in RR or LL homozygotes.
However, the distributions of polymorphisms did not differ between patients and controls, and the activity in each haplotype of the two polymorphisms was lower in the hemodialysis patients than in the controls.
Therefore, the two genetic polymorphisms are not causally related to the decrease in either paraoxonase or arylesterase activity in the hemodialysis patients.
In patients, each component of HDL (HDL-C, apo A-I and apo A-II concentration) was significantly lower than that in control subjects.
Therefore, the decrease in paraoxonase and arylesterase activities was somewhat accompanied by a decrease in apo A-I mass, because the ratio of paraoxonase activity/apo A-I concentration in patients was comparable with that in controls, and arylesterase activity/apo A-I concentration was rather higher in patients.
Although we did not measure PON1 mass in the subjects, it may be decreased by accompanying the reduced apo A-I, by accelerated catabolism or decreased production of PON1.
Some factors other than the decreased apo A-I mass could also affect the reduction of each activity. For example, metabolic change in the uremic milieu may modify the HDL composition or structure, which may possibly affect the active site of the enzyme resulting in a decrease in the activities.
In the present study, both paraoxonase and arylesterase activities were significantly correlated with serum apo A-I concentrations in the 
